444 related articles for article (PubMed ID: 29180611)
1. Screening drug effects in patient-derived cancer cells links organoid responses to genome alterations.
Jabs J; Zickgraf FM; Park J; Wagner S; Jiang X; Jechow K; Kleinheinz K; Toprak UH; Schneider MA; Meister M; Spaich S; Sütterlin M; Schlesner M; Trumpp A; Sprick M; Eils R; Conrad C
Mol Syst Biol; 2017 Nov; 13(11):955. PubMed ID: 29180611
[TBL] [Abstract][Full Text] [Related]
2. Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids.
Hill SJ; Decker B; Roberts EA; Horowitz NS; Muto MG; Worley MJ; Feltmate CM; Nucci MR; Swisher EM; Nguyen H; Yang C; Morizane R; Kochupurakkal BS; Do KT; Konstantinopoulos PA; Liu JF; Bonventre JV; Matulonis UA; Shapiro GI; Berkowitz RS; Crum CP; D'Andrea AD
Cancer Discov; 2018 Nov; 8(11):1404-1421. PubMed ID: 30213835
[TBL] [Abstract][Full Text] [Related]
3. Organoid Cultures Derived From Patients With Papillary Thyroid Cancer.
Chen D; Tan Y; Li Z; Li W; Yu L; Chen W; Liu Y; Liu L; Guo L; Huang W; Zhao Y
J Clin Endocrinol Metab; 2021 Apr; 106(5):1410-1426. PubMed ID: 33524147
[TBL] [Abstract][Full Text] [Related]
4. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening.
Broutier L; Mastrogiovanni G; Verstegen MM; Francies HE; Gavarró LM; Bradshaw CR; Allen GE; Arnes-Benito R; Sidorova O; Gaspersz MP; Georgakopoulos N; Koo BK; Dietmann S; Davies SE; Praseedom RK; Lieshout R; IJzermans JNM; Wigmore SJ; Saeb-Parsy K; Garnett MJ; van der Laan LJ; Huch M
Nat Med; 2017 Dec; 23(12):1424-1435. PubMed ID: 29131160
[TBL] [Abstract][Full Text] [Related]
5. Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors.
Maru Y; Tanaka N; Itami M; Hippo Y
Gynecol Oncol; 2019 Jul; 154(1):189-198. PubMed ID: 31101504
[TBL] [Abstract][Full Text] [Related]
6. Organoid Culture of Isolated Cells from Patient-derived Tissues with Colorectal Cancer.
Xie BY; Wu AW
Chin Med J (Engl); 2016 Oct; 129(20):2469-2475. PubMed ID: 27748340
[TBL] [Abstract][Full Text] [Related]
7. Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing.
Nanki Y; Chiyoda T; Hirasawa A; Ookubo A; Itoh M; Ueno M; Akahane T; Kameyama K; Yamagami W; Kataoka F; Aoki D
Sci Rep; 2020 Jul; 10(1):12581. PubMed ID: 32724113
[TBL] [Abstract][Full Text] [Related]
8. Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity.
Tanaka N; Osman AA; Takahashi Y; Lindemann A; Patel AA; Zhao M; Takahashi H; Myers JN
Oral Oncol; 2018 Dec; 87():49-57. PubMed ID: 30527243
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine.
Praharaj PP; Bhutia SK; Nagrath S; Bitting RL; Deep G
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):117-127. PubMed ID: 29360544
[TBL] [Abstract][Full Text] [Related]
10. Patient-Derived Organoids of Cholangiocarcinoma.
Maier CF; Zhu L; Nanduri LK; Kühn D; Kochall S; Thepkaysone ML; William D; Grützmann K; Klink B; Betge J; Weitz J; Rahbari NN; Reißfelder C; Schölch S
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445380
[TBL] [Abstract][Full Text] [Related]
11. Appendiceal Cancer Patient-Specific Tumor Organoid Model for Predicting Chemotherapy Efficacy Prior to Initiation of Treatment: A Feasibility Study.
Votanopoulos KI; Mazzocchi A; Sivakumar H; Forsythe S; Aleman J; Levine EA; Skardal A
Ann Surg Oncol; 2019 Jan; 26(1):139-147. PubMed ID: 30414038
[TBL] [Abstract][Full Text] [Related]
12. Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues.
Gao M; Lin M; Rao M; Thompson H; Hirai K; Choi M; Georgakis GV; Sasson AR; Bucobo JC; Tzimas D; D'Souza LS; Buscaglia JM; Davis J; Shroyer KR; Li J; Powers S; Kim J
Ann Surg Oncol; 2018 Sep; 25(9):2767-2775. PubMed ID: 30003451
[TBL] [Abstract][Full Text] [Related]
13. The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer.
Yan S; Xuan J; Brajanovski N; Tancock MRC; Madhamshettiwar PB; Simpson KJ; Ellis S; Kang J; Cullinane C; Sheppard KE; Hannan KM; Hannan RD; Sanij E; Pearson RB; Chan KT
Br J Cancer; 2021 Feb; 124(3):616-627. PubMed ID: 33173151
[TBL] [Abstract][Full Text] [Related]
14. High-throughput screening in colorectal cancer tissue-originated spheroids.
Kondo J; Ekawa T; Endo H; Yamazaki K; Tanaka N; Kukita Y; Okuyama H; Okami J; Imamura F; Ohue M; Kato K; Nomura T; Kohara A; Mori S; Dan S; Inoue M
Cancer Sci; 2019 Jan; 110(1):345-355. PubMed ID: 30343529
[TBL] [Abstract][Full Text] [Related]
15. Establishment of 2.5D organoid culture model using 3D bladder cancer organoid culture.
Abugomaa A; Elbadawy M; Yamanaka M; Goto Y; Hayashi K; Mori T; Uchide T; Azakami D; Fukushima R; Yoshida T; Shibutani M; Yamashita R; Kobayashi M; Yamawaki H; Shinohara Y; Kaneda M; Usui T; Sasaki K
Sci Rep; 2020 Jun; 10(1):9393. PubMed ID: 32523078
[TBL] [Abstract][Full Text] [Related]
16. Targeting the PI3K/mTOR Pathway Augments CHK1 Inhibitor-Induced Replication Stress and Antitumor Activity in High-Grade Serous Ovarian Cancer.
Huang TT; Brill E; Nair JR; Zhang X; Wilson KM; Chen L; Thomas CJ; Lee JM
Cancer Res; 2020 Dec; 80(23):5380-5392. PubMed ID: 32998994
[TBL] [Abstract][Full Text] [Related]
17. Advanced Development of Primary Pancreatic Organoid Tumor Models for High-Throughput Phenotypic Drug Screening.
Hou S; Tiriac H; Sridharan BP; Scampavia L; Madoux F; Seldin J; Souza GR; Watson D; Tuveson D; Spicer TP
SLAS Discov; 2018 Jul; 23(6):574-584. PubMed ID: 29673279
[TBL] [Abstract][Full Text] [Related]
18. Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract Carcinoma.
Saito Y; Muramatsu T; Kanai Y; Ojima H; Sukeda A; Hiraoka N; Arai E; Sugiyama Y; Matsuzaki J; Uchida R; Yoshikawa N; Furukawa R; Saito H
Cell Rep; 2019 Apr; 27(4):1265-1276.e4. PubMed ID: 31018139
[TBL] [Abstract][Full Text] [Related]
19. Drug Sensitivity Assays of Human Cancer Organoid Cultures.
Francies HE; Barthorpe A; McLaren-Douglas A; Barendt WJ; Garnett MJ
Methods Mol Biol; 2019; 1576():339-351. PubMed ID: 27628132
[TBL] [Abstract][Full Text] [Related]
20. ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.
Kaipio K; Chen P; Roering P; Huhtinen K; Mikkonen P; Östling P; Lehtinen L; Mansuri N; Korpela T; Potdar S; Hynninen J; Auranen A; Grénman S; Wennerberg K; Hautaniemi S; Carpén O
J Pathol; 2020 Feb; 250(2):159-169. PubMed ID: 31595974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
